ReleaseWire

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

Global Healthcare Providers industry guide provides top-line qualitative and quantitative summary information including: sector size (value 2009-13, and forecast to 2018). The guide also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the sector.

Parkinson's disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent leads to the development of symptoms associated with Parkinson's disease such as tremor, bradykinesia, and muscular rigidity. It is usually diagnosed in the population aged 60 and over; however, earlier incidences have been reported. Based on the severity, it can be categorized into early stage, mid stage and late (or advanced) stage. Currently, the approved therapies provide only symptomatic relief. Levodopa is the standard drug for the treatment of Parkinson's disease; however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson's disease patients under certain circumstances.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

GlobalData's clinical trial report, "Lower Limb Muscle Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Lower Limb Muscle Spasticity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lower Limb Muscle Spasticity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lower Limb Muscle Spasticity. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

GlobalData's clinical trial report, "Neuralgia Global Clinical Trials Review, H2, 2014" provides data on the Neuralgia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuralgia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuralgia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

Global Markets Direct's, 'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2014', provides an overview of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)'s therapeutic pipeline.

CEL-SCI Corporation today announced that during the month of July the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 47 patients were enrolled over the past three months, with 14 in May, 19 in June, and 14 in July. This marks a 15% increase over the prior three month period when a total of 41 patients were enrolled.

Global Markets Direct's, 'Mebiopharm Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Mebiopharm Co., Ltd.'s pharmaceutical research and development focus.

Global Markets Direct's, 'AcelRx Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the AcelRx Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

The NAFTA Healthcare Providers industry guide provides top-line qualitative and quantitative summary information including: sector size (value 2009-13, and forecast to 2018). The guide also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the sector.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

GlobalData's clinical trial report, "Muscle Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Muscle Spasticity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Muscle Spasticity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Muscle Spasticity. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Actinium Pharmaceuticals, Inc.,a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A. The center joins several other clinical trial sites currently participating in the Actimab-A Phase I/II trial to potentially address the rapid mortality and unmet medical need for older patients with newly diagnosed acute myeloid leukemia (AML).

The Scandinavian Healthcare Providers industry guide provides top-line qualitative and quantitative summary information including: sector size (value 2009-13, and forecast to 2018). The guide also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the sector.